ValuEngine downgraded shares of Xenon Pharmaceuticals (NASDAQ:XENE) from a hold rating to a sell rating in a report issued on Wednesday.
Separately, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a sell rating to a hold rating in a research note on Sunday, January 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. Xenon Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $6.33.
Xenon Pharmaceuticals (XENE) opened at $4.50 on Wednesday. Xenon Pharmaceuticals has a fifty-two week low of $2.10 and a fifty-two week high of $9.95. The company has a current ratio of 10.98, a quick ratio of 14.75 and a debt-to-equity ratio of 0.17.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sabby Management LLC boosted its stake in Xenon Pharmaceuticals by 7.1% in the 4th quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock worth $931,000 after purchasing an additional 21,800 shares during the period. K2 Principal Fund L.P. boosted its stake in Xenon Pharmaceuticals by 33.5% in the 4th quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock worth $620,000 after purchasing an additional 55,033 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Xenon Pharmaceuticals by 59.2% in the 4th quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock worth $703,000 after purchasing an additional 92,600 shares during the period. 50.90% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3253889/xenon-pharmaceuticals-xene-cut-to-sell-at-valuengine.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.